**WP9-NoE-Omics**

**WP9 12-month update (October 2022 - September 2023)**

Although NoE-Omics & NoE-Hitech medical resourcesremain separate, they have decided to work closely together due to their similar characteristics and common challenges.

The scope of the future network on Omics focuses on fostering the integration of omics technologies into all EU healthcare systems in order to improve clinical decisions in precision medicine in oncology (genetic susceptibility, diagnosis, treatment, follow-up, palliative care)  The scope of the future network on Hi-tech medical resources includes 5 domains considered as priorities: innovative radiotherapies, interventional radiology, innovative nuclear medicine, cell therapies and ex-vivo testing of agents.

As omics and hi-tech medical resources are innovative, very expensive and rather rare resources in the European cancer area, the future NoEs will have to respect the following principles: equal access to excellence and high quality services, fast integration of innovation into care and flexibility given the Member States’ specificities. The objectives of the future NoEs are being defined in synergy with other existing stakeholders, networks and projects at the EU and national levels. As omics and hi-tech medical resources evolve fast, the future network could act as an innovation observatory, warning of new innovative practices that are "ready" for use.

The endorsement criteria of NoEs on Omics and Hitech medical resources come under the following headings:

* Type and volume of activity
* Infrastructure, resources, capability
* Workflow, accessibility, collaboration

The endorsement participation criteria were defined in order to allow 3 categories of healthcare providers all around Europe to benefit from the future network. Those criteria needed to apply to care and had to remain simple, with a prerequisite of quality, inclusivity and a twinning approach.